Rituximab
Rituximab a,ɛyɛ adwumakuo Rituxan ne nnwumakuo ahodoɔ binom na wɔtɔn no,yɛ aduro a wɔde hwɛ nyarewa ahodoɔ bi ne kokoram yareɛ ahodoɔ binom.[1]
Yareɛ A Wɔde Sa
[sesa]Rituximab yɛ nnuro a wɔde ko tia CD20, a ɛwɔ B cells honam ani.Ɛyɛ adwuma sɛdeɛ ɛpepa B cells wedeɛ no ani no a ɛma plasma cells hematopoietic stem cells no a ɛnkyerɛ CD20 no.[2]
Nsunsuansoɔ
[sesa]Ɛho nsunsuansoɔ a ano yɛ den no tumi de owuo ba.
Abakɔsɛm
[sesa]IDEC nnuro adwumakuo a ɛhyɛ IDEC C2B8 na wɔyɛɛ Rituximab. US man a wɔyɛɛ aduro no de too dwa 1998 na ɛwuu wɔ 2015
Asetena Ne Amammerɛ
[sesa]Ekɔnɔmiks
[sesa]Wɔ 2014, Genentech sane hyehyɛɛ Rituxan sɛ aduro soronko, adurokuo a na ɛwɔ US,wɔn a wɔtɔn nnuro nko ara.Ɛfiri sɛ wɔn a wɔfa no atufoɔboɔ no rentua sika biara,na mmom asupiti na wɔbɛtua.
Nhwehwɛmu
[sesa]Myalgic encephalomyelitis/chronic fatigue syndrome
[sesa]Wɔ 2009,ayarefoɔ a wɔgye methotrexate B-cell no hunuu encephalomyelitis anaa sɛ koankorɔ(ME/CFS)ho mpopeɛ.
Beaeɛ A Menyaa Mmoa Firiiɛ
[sesa]- ↑ Rituximab Monograph for Professionals - Drugs.com, 2016-03-27, archived from the original on 2016-03-27, retrieved 2024-08-24
{{citation}}: CS1 maint: bot: original URL status unknown (link) - ↑ Abhishek De, Asad Ansari, Nidhi Sharma, Aarti Sarda (2017), "Shifting Focus in the Therapeutics of Immunobullous Disease", Indian Journal of Dermatology, vol. 62, no. 3, pp. 282–290, doi:10.4103/ijd.IJD_199_17, ISSN 0019-5154, PMC 5448263, PMID 28584371, retrieved 2024-08-24
{{citation}}: CS1 maint: multiple names: authors list (link)